☆ 4.7 Editorial Material

Cerebral Vein Thrombosis With Vaccine-Induced Immune Thrombotic Thrombocytopenia

STROKE (2021)

Related references

Note: Only part of the references are listed.

Article Emergency Medicine

Thrombotic complications of COVID-19

Jacob Avila et al.

Summary: Thrombotic complications associated with COVID-19, believed to be caused by a hyperinflammatory response, include various complications such as acute limb ischemia, myocardial infarction, and venous thromboembolism. It is important for Emergency Medicine clinicians to be knowledgeable about these complications to promptly recognize and treat them in order to reduce morbidity and mortality in patients.

AMERICAN JOURNAL OF EMERGENCY MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Cerebrovascular events and outcomes in hospitalized patients with COVID-19: The SVIN COVID-19 Multinational Registry

James E. Siegler et al.

Summary: COVID-19 is associated with a small but significant risk of cerebrovascular events, particularly ischemic stroke. The mortality rate is high for COVID-19-associated cerebrovascular complications, highlighting the importance of aggressive monitoring and early intervention.

INTERNATIONAL JOURNAL OF STROKE (2021)

Add to Collection

Article Neurosciences

Stroke and Thromboprophylaxis in the Era of COVID-19

Alice Ma et al.

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

J. Sadoff et al.

Summary: The study conducted a multicenter, placebo-controlled, phase 1-2a trial, with participants randomly assigned to receive the Ad26.COV2.S vaccine. The results showed that the safety and immunogenicity profiles of the vaccine support further development.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Critical Care Medicine

Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study

Lionel Piroth et al.

Summary: Patients hospitalized for COVID-19 and influenza in France showed significant differences in terms of hospitalization requirements, clinical characteristics, and outcomes, with COVID-19 patients more likely to develop severe complications and have higher mortality rates. In children, while hospitalization rate for COVID-19 appeared lower than for influenza, in-hospital mortality was higher, although limited by low patient numbers. These findings emphasize the need for appropriate preventive measures, specific vaccines, and treatments for COVID-19.

LANCET RESPIRATORY MEDICINE (2021)

Add to Collection

Review Neurosciences

Cerebral Venous Sinus Thrombosis in COVID-19 Patients: A Multicenter Study and Review of Literature

Mohamad Abdalkader et al.

Summary: COVID-19 infection can predispose patients to both arterial and venous thromboembolic events, including CVST. Reviewing the clinical and radiological presentation of CVST in COVID-19 positive patients revealed that patients often presented with symptoms like headache, fever, and gastrointestinal symptoms. Clinicians should be vigilant about the risk of acute CVST in patients positive for COVID-19.

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2021)

Add to Collection

Article Medicine, General & Internal

Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia

Denis Y. Logunov et al.

Summary: The Gam-COVID-Vac vaccine showed 91.6% efficacy against COVID-19 in the phase 3 trial, with good safety and tolerability in a large cohort of participants.

LANCET (2021)

Add to Collection

Editorial Material Medicine, General & Internal

SARS-CoV-2 variants and ending the COVID-19 pandemic

Arnaud Fontanet et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

News Item Medicine, General & Internal

Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant

Elisabeth Mahase

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Clinical Neurology

Cerebral Venous Thrombosis in COVID-19: A New York Metropolitan Cohort Study

F. Al-Mufti et al.

Summary: Among COVID-19 patients, the incidence of cerebral venous thrombosis is significantly higher than in the general population, with a male preponderance and most patients developing neurological symptoms within 24 hours of respiratory and constitutional symptoms.

AMERICAN JOURNAL OF NEURORADIOLOGY (2021)

Add to Collection

Article Immunology

Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination-A report of two UK cases

Puja R. Mehta et al.

Summary: Recent reports have highlighted rare cases of CVST and thrombocytopenia following Vaxzevria vaccination. An immunological mechanism similar to HIT, but without prior heparin exposure, is suspected. Management of such cases involves PF4 antibody testing and treatment similar to HIT.

BRAIN BEHAVIOR AND IMMUNITY (2021)

Add to Collection

Article Medicine, General & Internal

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination, March 2 to April 21, 2021

Isaac See et al.

Summary: Cases of CVST with thrombocytopenia following Ad26.COV2.S vaccination have been reported in the US, leading to serious outcomes. This case series may provide guidance for clinical management and further investigation into the potential relationship between Ad26.COV2.S vaccine and CVST with thrombocytopenia.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Katherine R. W. Emary et al.

Summary: A post-hoc analysis was conducted on the efficacy of the ChAdOx1 nCoV-19 vaccine against the B.1.1.7 variant of SARS-CoV-2 in the UK. The vaccine showed reduced neutralisation activity against the B.1.1.7 variant in vitro, but still demonstrated efficacy against the B.1.1.7 variant of the virus.

LANCET (2021)

Add to Collection

Article Infectious Diseases

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

Andrew J. Pollard et al.

Summary: The study evaluated the safety and immunogenicity of a two-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo against Ebola virus. The results showed that this regimen was safe, well tolerated, and induced long-lasting humoral and cellular immune responses.

LANCET INFECTIOUS DISEASES (2021)

Add to Collection

Article Clinical Neurology

Global Impact of COVID-19 on Stroke Care and IV Thrombolysis

Raul G. Nogueira et al.

Summary: The study revealed a global decline in stroke hospitalizations, IV thrombolysis, and interfacility IV thrombolysis transfers during the COVID-19 pandemic. Recovery of stroke hospitalization volume was observed in the later months of the pandemic.

NEUROLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Marie Scully et al.

Summary: 23 cases of thrombotic thrombocytopenia were reported after receiving the AstraZeneca vaccine, incited by antibodies to platelet factor 4 and unrelated to heparin therapy. Avoidance of platelet transfusion and consideration of nonheparin anticoagulant and intravenous immune globulin are recommended for treatment.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Nina H. Schultz et al.

Summary: This study reports five cases of venous thrombosis and thrombocytopenia occurring 7 to 10 days after receiving the ChAdOx1 nCoV-19 vaccine, suggesting a rare vaccine-induced immune thrombotic thrombocytopenia. The condition, which can lead to catastrophic outcomes such as cerebral venous sinus thrombosis, may be treated with intravenous immune globulin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Andreas Greinacher et al.

Summary: After vaccination with ChAdOx1 nCov-19, rare immune thrombotic thrombocytopenia can occur due to platelet-activating antibodies against PF4, resulting in various thrombotic events. Most patients in this case series were women, with fatal outcomes such as cerebral venous thrombosis and intracranial hemorrhage. Additional studies are needed to further investigate and understand this phenomenon.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study

Anton Pottegard et al.

Summary: This study assessed rates of cardiovascular and haemostatic events in Denmark and Norway after vaccination with the Oxford-AstraZeneca vaccine ChAdOx1-S, finding increased rates of venous thromboembolic events among recipients. Despite slightly higher rates of thrombocytopenia/coagulation disorders and bleeding, the overall safety outcomes were largely reassuring.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Public, Environmental & Occupational Health

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine — United States, March–April 2021

David K. Shay et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

Add to Collection

Letter Clinical Neurology

Impact of cerebral venous sinus thrombosis associated with COVID-19

Archana Hinduja et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Letter Critical Care Medicine

Cerebral venous sinus thrombosis associated with thrombocytopenia post-vaccination for COVID-19

Gian Paolo Castelli et al.

CRITICAL CARE (2021)

Add to Collection

Letter Infectious Diseases

An interactive web-based dashboard to track COVID-19 in real time

Ensheng Dong et al.

LANCET INFECTIOUS DISEASES (2020)

Add to Collection

Article Clinical Neurology

SARS-CoV-2 and Stroke in a New York Healthcare System

Shadi Yaghi et al.

STROKE (2020)

Add to Collection

Article Clinical Neurology

Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis The TO-ACT Randomized Clinical Trial

Jonathan M. Coutinho et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prevalence and Impact of Myocardial Injury in Patients Hospitalized With COVID-19 Infection

Anuradha Lala et al.

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial

Feng-Cai Zhu et al.

LANCET (2020)

Add to Collection

Article Clinical Neurology

Cerebral venous sinus thrombosis associated with SARS-CoV-2; a multinational case series

Ashkan Mowla et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)

Add to Collection

Review Hematology

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis

Stephan Nopp et al.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

Indications for the Performance of Intracranial Endovascular Neurointerventional Procedures A Scientific Statement From the American Heart Association

Clifford J. Eskey et al.

CIRCULATION (2018)

Add to Collection

Article Hematology

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia

Adam Cuker et al.

BLOOD ADVANCES (2018)

Add to Collection

Article Neurosciences

Cerebral Venous Thrombosis Associated with Intracranial Hemorrhage and Timing of Anticoagulation after Hemicraniectomy

Michael A. Pizzi et al.

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2016)

Add to Collection

Article Hematology

Risk factors for heparin-induced thrombocytopenia: Focus on Fcγ receptors

Jerome Rollin et al.

THROMBOSIS AND HAEMOSTASIS (2016)

Add to Collection

Article Neurosciences

Cerebral Venous Thrombosis Associated with Intracranial Hemorrhage and Timing of Anticoagulation after Hemicraniectomy

Michael A. Pizzi et al.

JOURNAL OF STROKE & CEREBROVASCULAR DISEASES (2016)

Add to Collection

Article Critical Care Medicine

Safety and Tolerability of High-Intensity Anticoagulation with Bivalirudin During Neuroendovascular Procedures

Ameer E. Hassan et al.

NEUROCRITICAL CARE (2011)

Add to Collection

Article Pathology

Platelet Factor 4/Heparin Antibodies in Blood Bank Donors

Marcie J. Hursting et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)

Add to Collection

Review Hematology

Acquired and Congenital Risk Factors associated with Cerebral Venous Sinus Thrombosis

Robert D. McBane et al.

THROMBOSIS RESEARCH (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.